Module 17
QP Responsibilities, EU GMP Annex 16 Batch Certification, Import/Export Compliance and Product Complaints
Course Overview
This course establishes a comprehensive, operationally grounded understanding of the Qualified Person role, the legal and regulatory framework within which QP obligations are exercised, and the import and export compliance requirements that affect how medicinal products move across regulatory jurisdictions.
The Qualified Person carries one of the most consequential personal compliance obligations in the pharmaceutical industry. Named on a manufacturing or import licence, personally accountable for each batch certification decision, and subject to direct regulatory action in the event of a failure, the QP operates at the intersection of science, law, commercial reality and patient safety. The weight of that accountability is not distributed across a team or absorbed by an organisation. It rests with the named individual. That is by design, and understanding why is the foundation on which this course is built.
The QP role is also widely misunderstood by the functions that support it. Batch certification is not a signature at the end of a process; it is a conclusion that a specific batch of medicinal product has been manufactured, controlled, released and, where imported, verified in a manner that meets the applicable marketing authorisation, GMP requirements and national regulatory obligations. Every department that contributes to that chain – production, QC, QA, warehouse, supply chain, engineering, regulatory affairs, procurement, IT and senior leadership affects whether the QP can make that conclusion reliably and with genuine confidence. This course is designed for practising QPs at all experience levels, those working towards QP status, and the quality, regulatory and operational professionals whose work directly supports QP decision-making. It addresses the legal basis of the role, the practical conduct of batch certification, the particular challenges of imported product certification, QP obligations under the Falsified Medicines Directive and serialisation framework, and the import and export compliance landscape within which these responsibilities are exercised. It also addresses the human and organisational pressures that QPs routinely face – commercial urgency, supply constraints, incomplete data, outsourced manufacturing chains and cross-border complexity and how to navigate them with defensible professional judgement.
Learning Outcomes
By the end of this course, learners will be able to:
- Explain the legal basis of the QP role in the EU and UK, including how QP status is obtained, what the manufacturing or import licence requires the QP to certify, and what personal accountability the role carries under pharmaceutical legislation.
- Describe the full scope of a batch certification review – the documentation, testing evidence, manufacturing records, deviation status, change control history and regulatory compliance elements the QP must be satisfied with before certifying a batch.
- Explain the additional requirements for imported product certification, including the equivalence provisions under the EU-UK trade framework, MRA-covered territories, and the specific checks required for product manufactured outside the EU, UK or recognised equivalent markets.
- Distinguish between the QP’s personal professional obligation and the organisational quality system obligations that support it, and explain how gaps in either create certification risk.
- Explain the QP’s obligations under the Falsified Medicines Directive and the EU and UK serialisation frameworks, including verification, decommissioning, and the consequences of serialisation system failures on batch release.
- Describe how GDP obligations interact with QP certification decisions for products entering distribution, including temperature-sensitive products, controlled substances, biological products and products with complex supply chains.
- Recognise how different departments and functions – production, QC, QA, warehouse, supply chain, engineering, regulatory affairs, procurement, IT and senior leadership – affect the integrity of the information on which QP certification decisions are based.
- Apply a defensible decision-making framework to QP certification under pressure, including how to assess incomplete data, manage commercial urgency, escalate unresolved quality concerns and document the basis of a certification decision.
- Explain the Site Master File requirements and how the SMF represents the manufacturing or import site to regulatory authorities.
- Identify the import and export compliance obligations relevant to pharmaceutical organisations operating across multiple markets, including manufacturing import authorisation requirements, country-specific import conditions and the regulatory consequences of supply chain non-compliance.
- Explain how QP CPD obligations should be approached and how regulatory change – new guidance, revised legislative requirements, updated ICH guidelines and evolving inspection expectations – should be incorporated into ongoing QP practice.
- Recognise situations requiring immediate escalation, including certification decisions based on incomplete or unreliable data, imported product with unresolved manufacturing site concerns, serialisation failures affecting batch traceability, and commercial or organisational pressure that conflicts with regulatory obligations.
- Apply EU GMP Annex 16 expectations to batch certification decisions, including the QP’s responsibility for the manufacturing chain, the use of confirmation by other QPs in multi-site manufacturing arrangements, the certification of imported batches and the handling of unexpected results, deviations and product defects within the Annex 16 framework.
- Distinguish between the QP confirmation, certification and ultimate release decisions, and apply the appropriate Annex 16 framework provisions across the multi-step manufacturing chains common in contract manufacturing, contract testing and outsourced packaging arrangements.
- Apply the requirements for managing product complaints under EU GMP Chapter 8, including the QP’s accountability for complaint review, the assessment of complaints for product defect significance, the escalation of complaints affecting batch quality decisions and the recall framework that applies when complaint investigation identifies a product defect requiring market action.
- Explain the interface between the manufacturing quality system and the marketing authorisation holder’s pharmacovigilance system, including the boundaries of QPPV responsibility versus QP responsibility, the categories of complaint that require pharmacovigilance handling, and the structured information flows between the two systems.
- Identify situations requiring recall consideration, including categories of product defect, recall classification by severity, the regulatory notification framework that applies and the QP’s role in recall decision-making.
Course Content
No other role in the pharmaceutical industry carries the same combination of personal legal accountability and operational dependence on others. The QP must be satisfied that a batch meets its certification requirements, but cannot manufacture, test, store, document or release that batch alone. Every QP certification decision is the end point of a chain that involves dozens of people, multiple systems, several departments and, frequently, more than one organisation. If any part of that chain produces unreliable information, the QP’s certification is built on a foundation that neither the QP nor the regulator can trust.
This creates a distinctive professional challenge. The QP must understand the quality system deeply enough to assess whether the information presented is reliable. They must understand the regulatory framework well enough to identify when a batch or a process sits outside its authorised parameters. They must understand the science well enough to evaluate whether a deviation, atypical result or out-of-specification investigation has been adequately resolved.
And they must be able to hold that position under commercial pressure, supply constraints and organisational urgency – because those pressures do not reduce the regulatory obligation; they simply make it harder to maintain.
The import and export dimension compounds this. Imported product certification requires the QP to be satisfied that product manufactured outside the EU or UK – potentially at a site the QP has never visited, in a regulatory environment different from the one they are most familiar with, through a supply chain that may involve multiple intermediaries – meets the requirements that would have applied had the product been manufactured at home. That is a significant professional judgement, and one that requires both regulatory knowledge and supply chain visibility.
For functions that support QP decision-making, this course is equally essential. A QC laboratory that produces unreliable data, a production team that raises incomplete deviation reports, a warehouse function that maintains inadequate temperature records, a regulatory affairs team that fails to communicate post-approval variation status, or an IT function that allows audit trail gaps in batch-critical systems can each place a QP in the position of making a certification decision on inadequate information. Understanding the QP’s obligation and what it depends on is not a specialist concern. It is a shared responsibility for everyone involved in batch release.
The legal basis of the QP role
The course opens by establishing the legislative foundation of the QP obligation. Learners will understand how the QP role is defined in EU pharmaceutical legislation, how UK legislation has maintained and adapted that framework post-Brexit, and what the manufacturing or import licence formally requires. This includes how QP eligibility is established under educational and practical experience requirements, how QP status is maintained, what the personal accountability of the role means in practice, and what regulatory actions have been taken against QPs when that accountability has not been met.
The course distinguishes between the QP as a named licence holder with personal obligations and the quality system that supports the QP’s ability to exercise those obligations. A QP who relies on a functioning quality system is not abdicating responsibility; they are operating as the role is designed to function. A QP who certifies product without adequate systemic support, or who allows commercial pressure to compromise their professional judgement, carries the consequences personally.
Batch Certification: the Full Scope of the QP Review
Batch certification is addressed in comprehensive operational detail. Learners will understand what the QP must be satisfied with before certifying a batch, including batch manufacturing records, in-process controls, deviations and their investigations, out-of-specification results and their resolution, environmental monitoring data, equipment and utility status, material and component traceability, analytical testing results, compliance with the marketing authorisation and registered specifications, change control status, label reconciliation and packaging records.
The course explains how to approach a batch certification review systematically and with appropriate risk-based focus – where to apply greatest scrutiny, how to assess whether a deviation investigation is genuinely resolved, when an open CAPA presents a certification risk, and how to document the basis of a certification decision in a way that is defensible under subsequent audit or regulatory scrutiny.
A section addresses the QP decision under pressure. Learners will understand how to assess incomplete data, how to apply professional judgement when the quality system has produced ambiguous signals, when to certify with appropriate caveats, when to defer certification pending further investigation, and when to refuse certification altogether. The course makes clear that the last of these options is not a failure; it is the quality system working as intended.
Imported Product Certification
Imported product certification is addressed with the depth it requires. Learners will understand the additional obligations that apply when certifying product manufactured outside the EU or UK, including what equivalence arrangements and mutual recognition agreements mean for the level of additional testing and verification required, and where no such arrangements exist, what the QP must independently verify.
The course covers the practical assessment of imported product, including review of the manufacturer’s GMP status, third-country batch testing requirements, assessment of manufacturing site inspection history, evaluation of the supply chain for falsification risk, serialisation and authentication requirements, and the documentation that must accompany imported batches. Particular attention is given to the complexity of global supply chains involving multiple manufacturing sites, contract testing laboratories, intermediate storage locations and logistics providers across different regulatory jurisdictions.
Learners will also understand the QP’s obligations when certifying product imported from territories covered by mutual recognition agreements – including the EU-US MRA, the EU-UK framework and bilateral arrangements – and when those arrangements do not apply or have been suspended for specific manufacturers.
The Falsified Medicines Directive and serialisation
The FMD obligations relevant to QP certification are addressed in full. Learners will understand the EU and UK serialisation requirements, how unique identifiers and tamper-evident features support the Falsified Medicines Directive’s anti-counterfeiting objectives, and what the QP’s responsibilities are in relation to serialisation at batch level. The course covers the verification and decommissioning obligations, what serialisation system failures mean for batch release, and how QP certification interacts with the national medicines verification organisation infrastructure.
Cross-Functional Accountability for QP Decision Quality
A dedicated section examines how different departments affect the reliability of the information on which QP certification depends. Production teams who raise vague or incomplete deviation reports make root cause assessment difficult. QC laboratories with data integrity weaknesses produce results the QP cannot fully trust. Warehouse functions with inadequate temperature monitoring records create uncertainty about storage condition compliance. Regulatory affairs teams who have not communicated variation approval status leave the QP uncertain whether the current process matches the registered dossier. Engineering teams who implement equipment changes outside change control create unassessed validation gaps. IT functions who allow audit trail deficiencies undermine the traceability of batch-critical electronic records. Each of these functions will understand, through this course, how their work directly affects the QP’s ability to certify product with genuine confidence – and what happens to supply continuity and regulatory standing when they do not.
Import and Export Compliance
The import and export compliance section addresses the broader regulatory framework within which pharmaceutical organisations manage cross-border product flows. This includes manufacturing import authorisation requirements, the conditions attached to import licences, Site Master File obligations, country-specific import requirements for key markets, customs and regulatory documentation, and the GDP obligations that apply to cross-border supply.
The course explains how import and export compliance interacts with QP certification decisions, supply chain design, qualified supplier management, third-party logistics arrangements and regulatory notification requirements. It also addresses the consequences of import compliance failures – product detention, import refusal, enforcement action, supply disruption and reputational damage – and how a well-managed import compliance programme reduces those risks.
GDP and the QP
The course addresses the relationship between QP obligations and Good Distribution Practice requirements. Learners will understand how GDP interacts with batch certification for products entering the distribution chain, including temperature-sensitive products, controlled substances, biological products and products with restricted distribution requirements. This section explains how the QP’s release decision connects to the downstream distribution obligations that protect product integrity between the manufacturing site and the patient.
Cpd and Maintaining QP Readiness
The final section addresses how QPs should approach their continuing professional development obligations and how regulatory change should be incorporated into ongoing QP
practice. This includes monitoring changes to EU GMP, UK GMP, ICH guidelines, EMA and MHRA guidance, new and revised Annexes, updated inspection expectations and case law from regulatory enforcement actions. Learners will understand how to build a structured approach to CPD that maintains genuine professional currency rather than satisfying a formal requirement through the minimum possible effort.
EU GMP Annex 16 batch certification in operational depth
A dedicated section addresses EU GMP Annex 16 in operational detail. Learners will understand the full scope of Annex 16 expectations: the QP’s responsibility for the manufacturing chain including all steps performed at the QP’s certifying site and at all upstream sites, the principle of QP confirmation between sites where manufacturing operations are distributed across multiple QPs at different sites, the certification of batches imported from outside the EU/EEA and the specific evidence required, the handling of unexpected results during manufacture and how these affect certification decisions, the management of deviations and how their impact on batch certification is assessed, and the framework for handling product defects identified post-release.
The course addresses the practical realities of multi-QP arrangements where Annex 16 confirmation chains operate. Contract manufacturing arrangements where the contract giver and contract acceptor each have a QP, multi-site internal manufacturing chains where intermediate manufacturing steps are performed at different sites with different QPs, and shared manufacturing arrangements where multiple products are manufactured across multiple sites are all addressed with the Annex 16 framework applied to each.
The Annex 16 expectations for sampling, testing and importation are addressed in operational depth. The conditions under which certain testing may be performed in third countries and accepted for EU batch certification, the requirements for additional sampling and testing at the importing site, the documentation required to support the import certification decision and the QP’s accountability for the import process are all addressed within the framework.
The section also addresses the handling of unexpected results, deviations and product defects within Annex 16. The framework provides specific expectations for these situations, and the practical application of those expectations to common scenarios is addressed in detail.
Product complaints and the pharmacovigilance interface
A dedicated section addresses product complaints and the interface between the manufacturing quality system and the pharmacovigilance system. Learners will understand the EU GMP Chapter 8 expectations for product complaint handling, the QP’s accountability for complaint review and the practical operation of complaint handling systems in pharmaceutical organisations.
The course addresses the categorisation of complaints by type and significance, the investigation framework that applies to complaints affecting batch quality, the recall consideration framework that applies when investigation identifies a product defect requiring market action, the recall classification system (Class I, II and III recalls) and the regulatory notification framework that applies to product defect issues.
The pharmacovigilance interface is addressed in operational depth. Learners will understand the boundary between QPPV (EU Qualified Person for Pharmacovigilance) responsibility and QP (Qualified Person for batch certification) responsibility, the categories of complaint that require pharmacovigilance handling under the EU pharmacovigilance framework, the structured information flows that should exist between the two systems and the practical challenges that arise when complaints sit on the boundary between quality and safety.
The course addresses common operational complications including complaints relating to falsified products, complaints relating to counterfeit packaging or labelling, complaints from healthcare professionals reporting adverse events, complaints relating to product accessibility or supply continuity and complaints that may originate from competitor or regulatory testing. Each is addressed with the framework applied to the operational reality.
Recall decision-making is addressed in its own right. Learners will understand how a recall decision is made, who must be involved, what regulatory notifications are required, how recall execution is managed across the distribution chain, how recalled product is reconciled and destroyed and how post-recall analysis supports future prevention.
- Practising Qualified Persons at all experience levels, including those new to the role and those refreshing or deepening their understanding of specific obligations.
- Professionals working towards QP eligibility who need a comprehensive understanding of the role and its regulatory context as part of their qualifying preparation.
- Deputy QPs and QP-designated back-up personnel responsible for supporting QP operations or standing in for the named QP.
- Quality Assurance Managers, Quality Directors and site quality leadership whose work directly supports QP decision-making.
- Regulatory Affairs professionals managing manufacturing licences, import licences, marketing authorisations, post-approval variations and regulatory submissions that affect QP certification.
- Supply chain, import/export and logistics professionals managing pharmaceutical product flows across regulatory jurisdictions.
- QC Managers and laboratory professionals whose data and investigation outputs form part of the QP certification review.
- Production and operations managers whose manufacturing records, deviation management and process compliance form part of the QP certification review.
- Engineering and validation professionals whose equipment qualification, change control and maintenance records affect the information available to the QP.
- Procurement and supplier quality professionals whose management of approved suppliers, materials and contract manufacturers affects the supply chain integrity the QP must assess.
- IT and digital professionals whose management of batch-critical electronic systems and data integrity affects the reliability of QP certification evidence.
- Senior leaders and executive teams who need to understand the QP obligation, the organisational conditions that support it, and the consequences of allowing commercial pressure to override professional certification judgement.
You will gain a comprehensive, operationally grounded understanding of QP obligations – the legal basis, the practical scope of certification review, the specific challenges of imported product, the FMD and serialisation obligations, and the professional judgement required to make defensible certification decisions under real-world conditions.
For those in functions that support the QP, this course provides the clarity needed to understand how your work connects to the most significant quality decision in pharmaceutical supply – and what it means for patient safety, supply continuity and regulatory standing when that connection fails.
Organisations benefit from QPs who understand the full scope of their obligations and supporting teams who understand what reliable QP decision-making depends on. This reduces the risk of inappropriate batch certifications, import compliance failures, serialisation gaps, and the regulatory and reputational consequences of enforcement action against a named licence holder.
A QP who is well supported by a competent, quality-aware team across production, QC, QA, warehouse, supply chain, regulatory affairs, engineering, procurement and IT makes better certification decisions faster, with less friction and greater confidence. That is not a marginal efficiency gain. It is the difference between a batch release process that works reliably and one that periodically produces the kind of surprise that nobody in the supply chain can afford.
- Comprehensive expert video content covering QP obligations, batch certification, imported product requirements, FMD and serialisation, import/export compliance and GDP.
- Real-world case studies from pharmaceutical manufacturing, import operations, QP certification practice, supply chain compliance and regulatory enforcement environments.
- Practical batch certification review exercises, including deviations, OOS investigations, imported product documentation and certification under pressure scenarios.
- Cross-functional scenarios showing how production, QC, QA, warehouse, supply chain, engineering, regulatory affairs, procurement and IT affect QP certification quality.
- Imported product certification exercises covering MRA-covered and non-MRA markets, supply chain risk assessment and third-country testing requirements.
- Serialisation and FMD compliance scenarios including system failures, verification obligations and batch release implications.
- Import and export compliance guidance including Site Master File requirements, country-specific import conditions and GDP obligations for cross-border supply.
- QP decision-making framework exercises covering incomplete data, commercial pressure, deferral and refusal scenarios.
- CPD planning guidance and regulatory change management for QP practice.
- Multi-choice assessment examination.
- Certificate of completion upon passing the assessment.
Course Details
Instructor(s):
Paul Palmer & Farah Nadeem
Level:
Mastery
Duration:
3.5 Hours
Type:
Instructor led
Launch Yourself Into The Future.
Join Academy Pharmaceutical Excellence to gain industry-leading knowledge and skills through our comprehensive courses designed for aspiring professionals.